/PRNewswire/ Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its.
The liquid biopsy has been developed by Datar Cancer Genetics to help diagnose brain tumors where a conventional biopsy is not possible. A prospective, blinded study by a research team
Datar Cancer Genetics, a world leader in non-invasive cancer screening and diagnostics, today announced that Dr. Sendurai Mani, Ph.D has joined their Scientific
Datar Cancer Genetics, a world leader in non-invasive cancer screening, diagnostics, and precision oncology, today announced that it has appointed Dr. Razelle